Biomarkers for epileptogenesis in patients with autoimmune epilepsy  

作　　者：Batool F.Kirmani Katherine Au Seema Mir Matthew Hogan Dennis Kim Pushpa Sharma 

机构地区：[1]Department of Neurosciences,INOVA Fairfax Medical Campus,Falls Church,VA 22042,USA [2]VCU School of Medicine,INOVA Fairfax Medical Campus,Falls Church,VA 22042,USA [3]Department of Anesthesiology,Uniformed Services University of Health Sciences,Bethesda,MD 20814,USA

出　　处：《Neuroimmunology and Neuroinflammation》2021年第2期81-100,共20页神经免疫与神经炎症（英文版）

摘　　要：Autoimmune epilepsy(AE)is a general term to describe recurrent seizures that have an immune-mediated origin.It is increasingly being recognized as a cause of epilepsy due to accumulating evidence supporting an immune-mediated pathogenesis in patients who have shown resistance to traditional antiepileptic drugs(AEDs).The diagnosis of AE is one of the exclusions.Currently,there are no strict diagnostic guidelines for AE,and it is similarly under-recognized.The importance of early diagnosis of AE cannot be overstated,as prompt immunotherapy is important for seizure reduction.Further investigations into potential biomarkers are needed for early detection of AE and include targeted immunotherapies in combination with AEDs.The goal of this review was to provide an overview of the following biomarkers that have been associated with AE:AMPAR,LGl1,CASPR2,DPPX,GABAAR,GABABR,GFAP,GlyR,mGluR5,NMDAR,VGCC(P/Q types),amphiphysin,ANNA-1,CRMP-5,GAD65,and Ma1/Ma2 antibodies.

关 键 词：Autoimmune epilepsy biomarkers drug-resistant seizures IMMUNOTHERAPY EPILEPTOGENESIS 

分 类 号：R74[医药卫生—神经病学与精神病学]